Clinical data | |
---|---|
Other names | 5-OCF3-DMT |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C13H15F3N2O |
Molar mass | 272.271 g·mol−1 |
3D model (JSmol) | |
| |
|
5-TFMO-DMT (5-(trifluoromethoxy)-DMT, 5-OCF3-DMT, 5-(trifluoromethoxy)-N,N-dimethyltryptamine) is a psychedelic tryptamine derivative related to drugs such as 5-MeO-DMT and DMT (DMT). It acts as an agonist at the 5-HT2A receptor with an EC50 of 127.2 nM.[1] It was shown to release serotonin (5-HT) from synaptosomal preparations, and to reduce immobility time in the forced-swim test in animal studies, suggesting that it might have antidepressant activity.[1]
See also
References
- 1 2 WO 2022/235927, Kruegel AC, "NOVEL TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS.", published 10 November 2022, assigned to Gilgamesh Pharmaceuticals, Inc..
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.